Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA

Klimek, Ludger; Pfaar, Oliver; Worm, Margitta; Bergmann, Karl‐Christian; Bieber, Thomas; Buhl, Roland; Buters, Jeroen; Darsow, U.; Keil, Thomas; Kleine-Tebbe, Jörg; Lau, Susanne; Maurer, Marcus; Merk, Hans F.; Mösges, Ralph; Saloga, Joachim; Staubach, Petra; Stute, Petra; Rabe, Klaus F.; Rabe, Uta; Vogelmeier, Claus; Biedermann, Tilo; Jung, Kirsten; Schlenter, Wolfgang; Ring, Johannes; Chaker, Adam; Wehrmann, Wolfgang; Becker, Sven; Mülleneisen, Norbert; Nemat, Katja; Czech, W.; Wrede, Holger; Brehler, Randolf; Fuchs, Thomas; Tomazic, Peter‐Valentin; Aberer, Werner; Fink-Wagner, Antje; Horak, Friedrich; Wöhrl, Stefan; Niederberger‐Leppin, Verena; Pali‐Schöll, Isabella; Portmann, Wolfgang; Roller‐Wirnsberger, Regina; Spranger, O.; Valenta, Rudolf; Akdis, Mübecell; Akdiş, Cezmi A.; Hoffmann‐Sommergruber, Karin; Jutel, Marek; Matricardi, Paolo Maria; Spertini, François; Khaltaev, Nikolaï; Michel, Jean‐Pierre; Nicod, Laurent; Schmid‐Grendelmeier, Peter; Hamelmann, Eckard; Jakob, Thilo; Werfel, Thomas; Wagenmann, Martin; Taube, Christian; Gerstlauer, Michael; Vogelberg, Christian; Bousquet, Jean; Zuberbier, Torsten

doi:10.5414/alx02147e

Cited by 24 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients not infected or who have recovered from the infection, AIT could be continued. These recommendations are conditional and could change as clinical data evolve [ 5 , 39 ].…”

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

“…It is especially important to continue AIT in patients with life-threatening conditions like in venom allergy. If venom AIT was stopped due to SARS-CoV-2 infection, it is unclear when it should be re-initiated because data from convalescent patients is scarce [ 39 ].…”

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

“…When using SCIT preparations, the injection intervals can be prolonged in patients who have recovered from COVID-19 or in whom an adequate SARS-CoV-2 antibody reaction is detected after (possibly asymptomatic) disease can start or continue AIT as planned [ 39 ].…”

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

“…General recommendations for AIT administration during COVID-19 outbreak [ 39 ]: The staff and all persons entering a practice/allergy department should take suitable measures for hand hygiene using soap and water or an alcohol-based hand disinfectant with an antiviral effect. Based on a case-by-case risk assessment, the use of PPE should be considered in the AIT setting.…”

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

See 3 more Smart Citations

Management of Allergic Diseases During COVID-19 Outbreak

Izquierdo-Domínguez

Rojas-Lechuga

Alobid

2021

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of Review The coronavirus disease 2019 (COVID-19) has challenged healthcare system capacities and safety for health care workers, reshaping doctor-patient interaction favoring e-Health or telemedicine. The pandemic situation may make difficult to prioritize patients with allergies diseases (AD), face-to-face evaluation, and moreover concern about the possible COVID-19 diagnosis, since COVID-19 shared many symptoms in common with AD. Being COVID-19 a novel disease, everyone is susceptible; there are some advances on vaccine and specific treatment. We evaluate existing literature on allergic diseases (AD): allergic rhinitis, asthma, food allergy, drug allergy, and skin allergy, and potential underlying mechanisms for any interrelationship between AD and COVID-19. Recent Findings There is inconclusive and controversial evidence of the association between AD and the risk of adverse clinical outcomes of COVID-19. AD patients should minimize hospital and face-to-face visits, and those who have used biologics and allergen immunotherapy should continue the treatment. It is essential to wear personal protective equipment for the protection of health care workers. Summary Social distancing, rational use of facemasks, eye protection, and hand disinfection for health care workers and patients deserve further attention and promotion. Teleconsultation during COVID-19 times for AD patients is very encouraging and telemedicine platform can provide a reliable service in patient care.

show abstract

“…In patients not infected or who have recovered from the infection, AIT could be continued. These recommendations are conditional and could change as clinical data evolve [ 5 , 39 ].…”

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

Section: Specific Allergic Treatments: Immunotherapy and Biological Mmentioning

confidence: 99%

See 2 more Smart Citations

Management of Allergic Diseases During COVID-19 Outbreak

Izquierdo-Domínguez

Rojas-Lechuga

Alobid

2021

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…Since then, numerous position papers and practical guidance for optimal care of patients have been published by international and national allergy societies [ 2 , 3 , 4 , 5 , 6 ]. In addition, recommendations for the use of immunomodulatory antibodies (biologicals) and allergen immunotherapy (AIT) products were formulated early during the pandemic and adapted to the German healthcare situation [ 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo

Pfaar

Klimek

Hamelmann

et al. 2021

ALS

Self Cite

View full text Add to dashboard Cite

Background: After the beginning and during the worldwide pandemic caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), patients with allergic and atopic diseases have felt and still feel insecure. Currently, four vaccines against SARS-CoV-2 have been approved by the Paul Ehrlich Institute in Germany, and vaccination campaigns have been started nationwide. In this respect, it is of utmost importance to give recommendations on possible immunological interactions and potential risks of immunomodulatory substances (monoclonal antibodies, biologicals) during concurrent vaccination with the approved vaccines. Materials and methods: This position paper provides specific recommendations on the use of immunomodulatory drugs in the context of concurrent SARS-CoV-2 vaccinations based on current literature. Results: The recommendations are covering the following conditions in which biologicals are indicated and approved: 1) chronic inflammatory skin diseases (atopic dermatitis, chronic spontaneous urticaria), 2) bronchial asthma, and 3) chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with atopic dermatitis or chronic spontaneous urticaria are not at increased risk for allergic reactions after COVID-19 vaccination. Nevertheless, vaccination may result in transient eczema exacerbation due to general immune stimulation. Vaccination in patients receiving systemic therapy with biologicals can be performed. Patients with severe asthma and concomitant treatment with biologicals also do not have an increased risk of allergic reaction following COVID-19 vaccination which is recommended in these patients. Patients with CRSwNP are also not known to be at increased risk for allergic vaccine reactions, and continuation or initiation of a treatment with biologicals is also recommended with concurrent COVID-19 vaccination. In general, COVID-19 vaccination should be given within the interval between two applications of the respective biological, that is, with a time-lag of at least 1 week after the previous or at least 1 week before the next biological treatment planned. Conclusion: Biologicals for the treatment of atopic dermatitis, chronic spontaneous urticaria, bronchial asthma, and CRSwNP should be continued during the current COVID-19 vaccination campaigns. However, the intervals of biological treatment may need to be slightly adjusted (DGAKI/AeDA recommendations as of March 22, 2021).

show abstract

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

Self Cite

113

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA

Cited by 24 publications

References 34 publications

Management of Allergic Diseases During COVID-19 Outbreak

Management of Allergic Diseases During COVID-19 Outbreak

COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About